‘Mama and I’ is a leading center for diagnosis and treatment of children with congenital anomalies

In just a year and a half, the newest and most modern clinic for mothers and children has become the leading center for diagnosis and treatment of children with congenital anomalies in the country. In the first six months since the clinic opened, 66 children have been diagnosed and treated at ‘Mama and I’, and in the past 2024, 229 children with such problems have been treated.

“The fact that more and more families are turning to us is proof of the success of the multidisciplinary approach we apply, the only one in the country,” said Dr Velimir Simov, head of the paediatrics department. “Our teams will continue to see, without fail and around the clock, the most severe cases. We are proud that at ‘Mama and I’ we are developing paediatrics very successfully and we strive to cover the whole pathology and the whole range of examinations to help children and their parents. Our goal is to provide quality medical genetic counseling, which is the basis of prevention of genetic diseases and their consequences,” says Dr. Simov.

All state-of-the-art diagnostic, treatment, technology and specialist options are available to young patients and their parents. Imaging, clinical laboratory, immunological and genetic tests are performed as quickly as possible and in one place. The paediatrics clinic employs specialists of European level whose expertise patients seek – Assoc. Maria Gaidarova, paediatric nephrologist, prof. Dobrin Konstantinov, paediatric oncohaematologist, prof. Stefan Stefanov, paediatric rheumatologist and others.

Many of the young patients have diagnoses whose etiology needs to be further refined. Follow-up for luxations is done by established paediatric orthopaedists and traumatologists under the guidance of Prof. Asparuh Asparuhov. Neuromuscular diseases, the whole spectrum of epilepsy, children with neuro-psychiatric development disorders, including autism, are consulted with the leading neurologist prof. Plamen Bojinov and his team. The genetic laboratory of ‘Mama and I’, under the leadership of Assoc. Elitsa Becheva-Kraichir, applies an algorithm of specialized tests for timely and accurate diagnosis, analysis, interpretation approaches and long-term follow-up.

“There is a bench in Stara Zagora, placed by the National Alliance of People with Rare Diseases in Bulgaria, which says: “There is an invisible city of 400 000 people with rare diagnoses in Bulgaria”. We have been talking about this for years – with individual specialists, with people from the Alliance, with patient organisations and with dozens of our patients. But there is no strategy at national level,” says Assoc.prof. Becheva-Kraichir.

The specialists remind that the best treatment is prevention and follow-up, before the development of symptoms and complications, and that this is how to work according to the most up-to-date directives for good medical practice, modern paediatrics and genetics.

Epilepsy through the eyes of a geneticist

Assoc. Dr. Elitza Betcheva-Krajcir: At ‘Heart and Brain’ every patient with epilepsy can receive a multidisciplinary approach, individual treatment plan and follow-up

Epilepsy is a group of diseases in which, due to brain involvement, there is a persistent predisposition to epileptic seizures of different nature. It is one of the most common pathological conditions in neurological practice, affecting more than 50 million people worldwide of different ages, genders and ethnic backgrounds. According to recent scientific data, up to about 10% of people in the general population in industrialized countries have at least one epileptic seizure in their lifetime, and at least 3% develop a disease in the epilepsy group. At the same time, over 80% of epilepsy-associated mortality is found in low- and middle-income countries. Over 13 million people per year develop varying degrees of disability as a result of epilepsy.

Few people know that genetics plays an important role in the diagnosis and treatment of the disease. At ‘Heart and Brain’ Pleven, medical genetics specialists work together with paediatricians, neurologists, imaging specialists, clinical laboratory doctors and immunologists. It is this multidisciplinary approach that allows the most appropriate individual treatment and follow-up plan to be determined in the shortest possible time.

On the International Day of People with Epilepsy, we talk to Dr. Elitsa Becheva-Kraichir, Head of the Medical Genetics Laboratory at ‘Heart and Brain’ Pleven and Burgas.

– Assoc. Betcheva, please tell us a bit more about epilepsy and epileptic seizures.

– By definition, seizures are the symptoms of an irregular release of electrical charges from a large group of nerve cells in the brain, resulting in tingling sensations, smells, altered consciousness or twitching of muscles, entire limbs or convulsions of the whole body. The occurrence of such seizures at different points in time, with or without immediate provocation, is epilepsy. When, in addition to epileptic seizures, there is also involvement of higher functions of the cerebral cortex, we speak of epileptic encephalopathy. And when symptoms from other organs and systems are found in addition to epilepsy (so-called co-morbidity), we speak of syndromic epilepsy.

The diseases in the group of epilepsies are diverse – they differ in the type and duration of seizures, the severity of symptoms, the presence of concomitant other complaints and causes of occurrence. Epilepsy may be due to severe brain trauma, intoxication, infectious diseases, congenital structural defects, brain tumors, brain degenerative diseases, metabolic diseases, vascular problems (stroke), genetic predisposition. But even with a thorough analysis of the causes, nearly half of the cases remain with an unknown etiology.

– What is the role of genetic factors in the occurrence of epilepsy?

– A significant proportion of genetically determined cases of epilepsy have a multifactorial basis, with only part of the causes of the disease being in our genetic information – DNA – while another part is due to environmental and lifestyle factors. In such cases, simple diagnostic genetic analyses will not be able to provide us with clinically relevant information.

When genetically determined epilepsy is due to individual genetic variants, these can already be detected by diagnostic genetic tests, but they are inherently different types, necessitating the use of different types of genetic analyses, because there is no method that covers all possible variations. In some patients we use molecular cytogenetic methods (e.g. microarray for variants called ‘copy number changes’), in others molecular genetic methods (sequencing or genotyping of single nucleotide variants), and in others, although rarely, specific ways of analysing DNA misrepeats (dynamic mutations) or defects in mitochondrial DNA.

– Tell us how you, the geneticists at Heart and Brain, work together with other specialists and what the multidisciplinary, individual approach you take entails.

– In the heterogeneous group of epilepsies, two main groups of patients stand out – paediatric and non-paediatric, and the approach to them diagnostically and therapeutically is sometimes slightly different.

When it comes to children with epilepsy, with or without encephalopathy and accompanying other symptoms, they are most often patients of the specialised clinic ‘Mom and Me’, part of Heart and Brain’. Alongside the care of the specific health problem for which they are hospitalised, specialist consultations are initiated with a geneticist and a neurologist. Laboratory, immunological, infectious disease tests, imaging, and EEG (electroencephalogram) are performed as needed. Specialists from different specialties discuss the case together and decide on genetic testing.

Unlike other tests, genetic analyses take some time (1-2 months). We invite the family for a secondary consultation, during which we explain in detail all our actions, tests, changes found, their consequences, preventive and therapeutic options in a language that people understand. The relatives of the sick child have the opportunity to ask all their questions. After the consultation, we provide a detailed written conclusion with recommendations according to the most current professional guidelines.

Often, the child needs long-term follow-up – not only from the pediatrician and neurologist, but also from other specialists such as the cardiologist and endocrinologist.

Sometimes the necessary preventive checkups are many in number, highly specialized and annual. To reduce the time and stress for children and their families, we have made arrangements for them to take place in just 2-3 days at one location. Children don’t have to ‘go to the doctors’, the specialist doctors come to them.

Like our young patients, adults with epilepsy or other neurological conditions that might have a genetic cause have the opportunity to have a genetic consultation on-site – in their hospital room, during their stay in the neurology clinic. The most common concern of these patients is what is the risk that their (now born, grown or future) children may also have a genetic disorder.

– What does the genetic consultation involve?

– At the first meeting of the genetic doctor with the patient (and his/her family), the specialist explains in understandable language the principles of genetic information, genetic testing and the genetic components of diseases. It is important for the patient to overcome the fear of the unknown and stigma, and for the doctor to understand and feel his patient psychologically.

The secondary consultation consists of one or more discussions between the geneticist and the patient and a written conclusion. The focus here is understanding the results and discussing next steps. Often, with chronic and complex diseases, patients and their families maintain contact with their doctor for years and have multiple, for example annual, secondary consultations.

– What specific tests are needed?

– As I mentioned, there is no method in genetics (yet) that allows us to test for all types of genetic changes with one test. However, there are already methods developed that allow searching for several types of genetic defects at the same time.

In general, in most cases the indication for genetic analysis is reached when other causes of the disease have been ruled out by more conventional methods. In the case of epilepsies, laboratory, infectious disease, imaging, physiological and other studies have already been performed, but the suspicion of a genetic etiology remains.

On the basis of the clinical picture, the presumed clinical diagnosis of the neurologist and the results of other investigations, the geneticist considers which method is most likely to identify the cause. In most cases, as a first step, we apply analysis for small DNA variants combined with analysis for copy-number changes, preferably covering nuclear and mitochondrial genetic material. We can examine only genes known to be associated with the development of epilepsy as well as all of a person’s protein-coding genes or even their entire genome. If we do not identify a genetic cause with these generally general methods, we undertake more specific investigations – for example, for dynamic mutations, epigenetic changes, etc.

– What is the point of genetic analyses in epilepsy and what are the benefits for the patient?

– This is a question that people often ask – “what’s the use when my gene can’t be fixed?”. There are several forms of epilepsy where identifying a specific genetic defect is key to the choice of therapy. For example, some forms of epilepsy are significantly affected by a special dietary regimen. In other forms of epilepsy, a specific genetic defect may cause the disease not to improve but, on the contrary, to worsen significantly with classical therapy (e.g. valproates). The genetic result helps us to understand why this is so and what medications are appropriate.

For other people with epilepsy, the most important question is what is the risk that the next child in the family will be affected by the same disease. When it comes to severe syndromic epilepsy with encephalopathy, determining the risk for recurrence and offering options for prenatal or preimplantation diagnosis is of great importance to parents.

Not least among the benefits for many families is the sense of relief that they finally know why their child, for example, is ill and the lifting of guilt, especially from mothers who often think they did something wrong during pregnancy.

Knowing the exact genetic diagnosis does not always allow an etiological treatment (treatment of the cause), but increasingly it allows the choice of a much better, more adequate treatment for the specific patient, a better quality of life and a system of measures to avoid the development of complications and disability.

The Bulgarian Cardiac Institute presented the first “Golden Heart of the Year” Awards for 2024

At a solemn ceremony yesterday in Burgas, the Bulgarian Cardiology Institute awarded the doctor who received the most positive evaluations from patients in the past year. The event was held at the Brasserie Sursum Corda on the premises of the Heart and Brain Hospital and brought together the nominated doctors, heads of clinics and departments, public figures and the media.

Dr. Embie Azis, leading cardiologist at ‘Heart and Brain’ Burgas, won the “Golden Heart of the Year” award with a remarkable result generated by hundreds of letters of thanks and positive feedback from patients and their families in surveys, the Internet and social networks. This recognition is high praise for her professionalism, but most of all for her unconditional dedication to patients, heartfelt attitude, attention and care. This award is proof that a doctor’s true value is not measured only by his knowledge and skills, but also by his humanity towards the people he treats.

“This recognition means a lot to me. I love my patients!” said Dr Azis excitedly.

The competition was extremely strong, with very close results between the top candidates from different specialties. Each of the nominated physicians demonstrated high medical qualities and impeccable attention to patients.

The summary of the results highlighted several key aspects that set , Heart and Brain’ apart from all the others. Patients expressed their admiration for the high-tech equipment and modern treatment methods. But it’s not just the technology that’s important, they note – it’s the comfortable environment created where they are relaxed and cared for during treatment that is key. Patients also emphasise that the doctors’ sincere and human communication with them and their relatives helps them to overcome their worries quickly. Each step of the treatment is explained clearly and with attention to detail, and this helps them feel confident and relaxed.

To ensure objectivity and that patients can express their opinions freely without any external pressure, anonymous surveys are central to determining the Big Golden Heart of the Year winner. The results show that Dr. Azis has managed to gain the trust and respect of everyone who has met her.

“We congratulate Dr Azis on this well-deserved recognition and thank her for her tireless work, professionalism and attitude that inspires the teams at , Heart and Brain’. All the nominated doctors are role models – thanks to them, our hospitals continue to be a place where patients receive the best treatment and care,” said Prof. Toni Vekov, Chairman of the Board of Directors of the Bulgarian Cardiac Institute.

Assoc. Prof. Natalia Chilingirova, MD: Prevention and screening are the key in the fight against cancer in Bulgaria

On World Cancer Day we talk to Assoc. Chilingirova, head of the complex oncology center in ‘Heart and Brain’ Pleven – the only Bulgarian member of the European organization of cancer institutes

– Assoc. Prof. Chilingirova, what do the latest World Health Organization data on cancer show?

– Every year, almost 20 million people hear the severe diagnosis and about 9.7 million die from the disease. However, it is important to know that around 40% of cancers can be prevented by avoiding risk factors and implementing prevention strategies that have been proven to work. The spread and severity of these diseases can also be reduced by early detection of new cases and timely therapeutic management. Many cancers have a high chance of cure if diagnosed early and treated adequately.

In 2020, 2.7 million people were diagnosed with cancer in the European Union and 1.3 million people died from the disease. It is expected that cancer mortality in Europe will rise by more than 24% by 2035.

But beyond the statistics, every patient is first and foremost a person, with his or her own destiny. The oncologist’s mission is to be with their patients throughout the process – together they choose the best treatment strategy and achieve the best possible quality of life.

– What is the situation in Bulgaria?

– To a large extent, Bulgaria follows the global trends in morbidity and mortality, lung cancer is the most frequently diagnosed malignancy in men and breast cancer in women. Unfortunately, however, most cancers are diagnosed at an advanced stage. The lack of long-term national policies on screening and prevention remains a problem, as does the inability to diagnose most cancers early. The appearance of symptoms is generally indicative of advanced disease, so it is important to see a doctor and have annual screening.

– Just a few days ago, an international scientific conference related to innovations in oncology concluded. Please tell us more.

– It focused on a multidisciplinary approach and communication. I was impressed by the lively discussions and the rooms full of medical professionals because I believe that this is where solutions and great ideas are born. Colleagues from Bulgaria and abroad took part, from different specialties, but united around the cause of fighting cancer. And the key to success is a team approach. Central in the discussions took the new possibilities of medicine and pharmacy in the fight against the disease, the possibilities of artificial intelligence as an additional tool to help the diagnosis of treatment.

We commented on new therapeutic options in the treatment of lung cancer. We focused on the key role of genetics in modern diagnosis and treatment, discussed new therapeutic options in the treatment of melanoma, and addressed the important role of screening and prevention with a focus on cervical cancer. We showed innovations in surgical approaches -robot-assisted surgery, presented our own data and analyses from clinical practice. In short, we dove into the infinity of modern diagnostic and treatment options, with an eye to the future of medicine.

– What are the takeaways and what are your goals for fighting cancer from here?

– Science is moving forward, and with it the fight against cancer. If I can summarise, I would say that our successes in the war against this disease are based on tireless teamwork and innovation at every stage from diagnosis through treatment and patient follow-up.

It makes sense that in this era of precision medicine and innovation in oncology, we should focus on advanced prevention and screening options to make a positive change to the dismal statistics. Early detection necessitates the introduction of digital technologies and platforms, telemedicine into actual clinical practice. And the goal is to offer adequate screening to target populations (patients at increased risk of disease), e.g. for breast, cervical, lung, colorectal cancer, etc. Such programmes are already underway in a number of other countries at national level.

Another crucial prerequisite for an excellent therapeutic response and good long-term outcomes is the availability of comprehensive cancer centres, where every step from diagnosis through treatment and follow-up happens in one place, without the patient and their relatives having to wander between separate institutions at such a difficult time.

‘Heart and Brain’ is an example of this. For nearly five years now, the comprehensive cancer centre has been applying a modern, multidisciplinary and high-tech world-class approach – in one place. Not surprisingly, we are the only full member and the first Bulgarian member of the largest network of oncology centres and institutions in Europe (OECI).

– What more needs to be done in terms of prevention?

– Prevention and screening are the key to fighting cancer – given the main risk factors for cancer, we could largely prevent or avoid them. For example, smoking is clearly associated with lung cancer, i.e. reducing and stopping it would reduce the risk of developing this cancer. Regular check-ups and vaccination would reduce the incidence of cervical cancer. Vaccines against the human papilloma virus, some of whose subtypes cause cervical cancer, are available in this country and can be administered. Above all, responsibility for health is a matter of personal choice.

Part of the process is raising public awareness, social engagement and providing relevant, accessible and accurate medical information.